Cartesian Therapeutics (RNAC) News Today $9.16 +0.01 (+0.11%) Closing price 05/23/2025 04:00 PM EasternExtended Trading$9.11 -0.05 (-0.55%) As of 05/23/2025 04:04 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock RNAC Latest News All Sources Trusted Sources MarketBeat Benzinga Bloomberg GlobeNewswire GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent May 2025 April 2025 March 2025 February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 Time Period HC Wainwright Issues Pessimistic Forecast for RNAC EarningsCartesian Therapeutics, Inc. (NASDAQ:RNAC - Free Report) - Investment analysts at HC Wainwright reduced their Q2 2025 earnings per share (EPS) estimates for shares of Cartesian Therapeutics in a note issued to investors on Monday, May 19th. HC Wainwright analyst M. Kapoor now expects that the comMay 23 at 7:49 AM | marketbeat.comHC Wainwright Analysts Decrease Earnings Estimates for RNACMay 23 at 1:39 AM | americanbankingnews.comWhat is HC Wainwright's Forecast for RNAC Q1 Earnings?Cartesian Therapeutics, Inc. (NASDAQ:RNAC - Free Report) - Research analysts at HC Wainwright issued their Q1 2026 EPS estimates for shares of Cartesian Therapeutics in a research note issued on Monday, May 19th. HC Wainwright analyst M. Kapoor anticipates that the company will post earnings perMay 22 at 7:07 AM | marketbeat.comCartesian Therapeutics, Inc. (NASDAQ:RNAC) Receives Average Recommendation of "Moderate Buy" from AnalystsCartesian Therapeutics, Inc. (NASDAQ:RNAC - Get Free Report) has earned an average rating of "Moderate Buy" from the eight analysts that are presently covering the company, Marketbeat reports. Two equities research analysts have rated the stock with a hold rating and six have given a buy rating toMay 22 at 3:24 AM | marketbeat.comResearch Analysts Offer Predictions for RNAC Q1 EarningsMay 22 at 2:07 AM | americanbankingnews.comCitadel Advisors LLC Has $5.64 Million Stake in Cartesian Therapeutics, Inc. (NASDAQ:RNAC)Citadel Advisors LLC trimmed its position in shares of Cartesian Therapeutics, Inc. (NASDAQ:RNAC - Free Report) by 16.2% during the fourth quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 315,000 shares of the company'May 20, 2025 | marketbeat.comCartesian Therapeutics, Inc. (NASDAQ:RNAC) Shares Bought by MPM Bioimpact LLCMPM Bioimpact LLC raised its position in Cartesian Therapeutics, Inc. (NASDAQ:RNAC - Free Report) by 14.6% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 721,139 shares of the company's stock after purchasing an additionMay 16, 2025 | marketbeat.comCantor Fitzgerald Issues Negative Estimate for RNAC EarningsCartesian Therapeutics, Inc. (NASDAQ:RNAC - Free Report) - Equities researchers at Cantor Fitzgerald decreased their FY2025 earnings per share estimates for shares of Cartesian Therapeutics in a report released on Monday, May 12th. Cantor Fitzgerald analyst K. Kluska now expects that the companyMay 16, 2025 | marketbeat.comCantor Fitzgerald Has Negative View of RNAC FY2025 EarningsMay 16, 2025 | americanbankingnews.comCartesian Therapeutics (NASDAQ:RNAC) Releases Earnings Results, Misses Estimates By $0.07 EPSCartesian Therapeutics (NASDAQ:RNAC - Get Free Report) announced its quarterly earnings results on Thursday. The company reported ($0.68) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.61) by ($0.07). The business had revenue of $1.10 million for the quarter, compared to analysts' expectations of $0.69 million.May 12, 2025 | marketbeat.comAnalysts Are Bullish on Top Healthcare Stocks: Harrow Health (HROW), Cartesian Therapeutics (RNAC)May 11, 2025 | theglobeandmail.comCartesian Therapeutics (RNAC) Gets a Buy from Mizuho SecuritiesMay 11, 2025 | theglobeandmail.comCartesian Therapeutics, Inc. (NASDAQ:RNAC) Just Released Its First-Quarter Results And Analysts Are Updating Their EstimatesMay 11, 2025 | finance.yahoo.comCartesian Therapeutics (RNAC) to Release Quarterly Earnings on WednesdayCartesian Therapeutics (NASDAQ:RNAC) will be releasing earnings before the market opens on Wednesday, May 14. (View Earnings Report at https://www.marketbeat.com/earnings/reports/2025-5-14-selecta-biosciences-inc-stock-1/)May 9, 2025 | marketbeat.comCartesian Therapeutics Reports First Quarter 2025 Financial Results and Provides Business UpdateMay 8, 2025 | globenewswire.com683 Capital Management LLC Has $2.24 Million Stock Holdings in Cartesian Therapeutics, Inc. (NASDAQ:RNAC)683 Capital Management LLC grew its holdings in shares of Cartesian Therapeutics, Inc. (NASDAQ:RNAC - Free Report) by 65.7% in the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 125,000 shares of the company's stock aftMay 4, 2025 | marketbeat.comCartesian Therapeutics Announces New Employment Inducement GrantsMay 2, 2025 | globenewswire.comCartesian Therapeutics, Inc. (NASDAQ:RNAC) Shares Purchased by Geode Capital Management LLCGeode Capital Management LLC raised its stake in Cartesian Therapeutics, Inc. (NASDAQ:RNAC - Free Report) by 63.0% in the 4th quarter, according to its most recent filing with the SEC. The fund owned 221,257 shares of the company's stock after purchasing an additional 85,557 shares during the perioApril 29, 2025 | marketbeat.comCartesian Therapeutics, Inc. (NASDAQ:RNAC) Given Consensus Recommendation of "Moderate Buy" by BrokeragesShares of Cartesian Therapeutics, Inc. (NASDAQ:RNAC - Get Free Report) have been given an average rating of "Moderate Buy" by the eight brokerages that are presently covering the stock, Marketbeat Ratings reports. Two investment analysts have rated the stock with a hold recommendation and six haveApril 27, 2025 | marketbeat.comCartesian Therapeutics management to meet with BTIGApril 26, 2025 | markets.businessinsider.comJPMorgan Chase & Co. Sells 34,278 Shares of Cartesian Therapeutics, Inc. (NASDAQ:RNAC)JPMorgan Chase & Co. reduced its position in Cartesian Therapeutics, Inc. (NASDAQ:RNAC - Free Report) by 11.1% in the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 274,740 shares of the company's stock after selling 34,278 sharesApril 21, 2025 | marketbeat.comNeedham & Company LLC Reaffirms Buy Rating for Cartesian Therapeutics (NASDAQ:RNAC)Needham & Company LLC reissued a "buy" rating and issued a $41.00 price target on shares of Cartesian Therapeutics in a report on Wednesday.April 11, 2025 | marketbeat.comHC Wainwright Reaffirms "Buy" Rating for Cartesian Therapeutics (NASDAQ:RNAC)HC Wainwright reiterated a "buy" rating and issued a $40.00 target price on shares of Cartesian Therapeutics in a report on Wednesday.April 11, 2025 | marketbeat.com1RNAC : Cartesian Therapeutics Reports Strong 12-Month Data For Lead Cell Therapy In...April 9, 2025 | benzinga.comMizuho Securities Sticks to Its Buy Rating for Cartesian Therapeutics (RNAC)April 9, 2025 | markets.businessinsider.comCartesian Therapeutics Shares Rise on Positive Phase 2b Trial ResultsApril 8, 2025 | marketwatch.comCartesian Therapeutics' Descartes-08 Observed to Provide Deep and Sustained Benefits Through Month 12 After a Single Course of Therapy in Phase 2b Myasthenia Gravis TrialApril 8, 2025 | globenewswire.comCartesian Therapeutics Announces New Employment Inducement GrantsApril 2, 2025 | globenewswire.comCartesian Therapeutics to Participate in the 24th Annual Needham Virtual Healthcare ConferenceApril 1, 2025 | globenewswire.comCartesian Therapeutics, Inc. (NASDAQ:RNAC) Given Consensus Recommendation of "Moderate Buy" by AnalystsCartesian Therapeutics, Inc. (NASDAQ:RNAC - Get Free Report) has been given a consensus rating of "Moderate Buy" by the ten brokerages that are covering the company, Marketbeat reports. Two research analysts have rated the stock with a hold rating and eight have assigned a buy rating to the compaApril 1, 2025 | marketbeat.comSubstantial Insider Buying: American Express, Asana, and MoreMarch 30, 2025 | 247wallst.comTimothy Springer Spends US$1.4m On Cartesian Therapeutics StockMarch 23, 2025 | finance.yahoo.comAnalysts Set Expectations for RNAC FY2025 EarningsCartesian Therapeutics, Inc. (NASDAQ:RNAC - Free Report) - Cantor Fitzgerald issued their FY2025 EPS estimates for Cartesian Therapeutics in a report issued on Monday, March 17th. Cantor Fitzgerald analyst K. Kluska expects that the company will post earnings of ($3.65) per share for the year. CaMarch 20, 2025 | marketbeat.comOppenheimer Reaffirms Their Hold Rating on Cartesian Therapeutics (RNAC)March 17, 2025 | markets.businessinsider.comErste Asset Management GmbH Has $3.26 Million Position in Cartesian Therapeutics, Inc. (NASDAQ:RNAC)Erste Asset Management GmbH lowered its stake in shares of Cartesian Therapeutics, Inc. (NASDAQ:RNAC - Free Report) by 93.6% in the fourth quarter, according to its most recent disclosure with the SEC. The fund owned 173,566 shares of the company's stock after selling 2,527,000 shares during the peMarch 16, 2025 | marketbeat.comCartesian Therapeutics, Inc.: Cartesian Therapeutics Reports Full Year 2024 Financial Results and Provides Business UpdateMarch 16, 2025 | finanznachrichten.deHC Wainwright Issues Pessimistic Forecast for Cartesian Therapeutics (NASDAQ:RNAC) Stock PriceHC Wainwright reduced their target price on Cartesian Therapeutics from $45.00 to $40.00 and set a "buy" rating for the company in a report on Friday.March 15, 2025 | marketbeat.comNeedham & Company LLC Reaffirms "Buy" Rating for Cartesian Therapeutics (NASDAQ:RNAC)Needham & Company LLC restated a "buy" rating and set a $41.00 price objective on shares of Cartesian Therapeutics in a research note on Thursday.March 14, 2025 | marketbeat.comCartesian Therapeutics Advances mRNA Therapy PipelineMarch 14, 2025 | tipranks.comAnalysts Offer Insights on Healthcare Companies: Cartesian Therapeutics (RNAC) and ProQR (PRQR)March 14, 2025 | markets.businessinsider.comCartesian Therapeutics Reports Full Year 2024 Financial Results and Provides Business UpdateMarch 13, 2025 | finance.yahoo.comTD Cowen Sticks to Its Buy Rating for Cartesian Therapeutics (RNAC)March 13, 2025 | markets.businessinsider.comCartesian Therapeutics announces employment inducement grantMarch 6, 2025 | markets.businessinsider.comCartesian Therapeutics Announces New Employment Inducement GrantMarch 6, 2025 | globenewswire.comCartesian Therapeutics, Inc. (NASDAQ:RNAC) Given Consensus Rating of "Moderate Buy" by AnalystsShares of Cartesian Therapeutics, Inc. (NASDAQ:RNAC - Get Free Report) have earned a consensus rating of "Moderate Buy" from the ten ratings firms that are currently covering the company, MarketBeat reports. Two analysts have rated the stock with a hold rating and eight have assigned a buy ratingMarch 6, 2025 | marketbeat.comCartesian Therapeutics (RNAC) Projected to Post Earnings on ThursdayCartesian Therapeutics (NASDAQ:RNAC) will be releasing earnings before the market opens on Thursday, March 6, Financial Modeling Prep reports.February 27, 2025 | marketbeat.comCartesian Therapeutics to Participate in Upcoming Investor ConferencesFebruary 18, 2025 | globenewswire.comFY2024 Earnings Forecast for RNAC Issued By Leerink PartnrsCartesian Therapeutics, Inc. (NASDAQ:RNAC - Free Report) - Investment analysts at Leerink Partnrs upped their FY2024 EPS estimates for shares of Cartesian Therapeutics in a note issued to investors on Wednesday, February 5th. Leerink Partnrs analyst T. Smith now expects that the company will postFebruary 10, 2025 | marketbeat.comCartesian Therapeutics, Inc. (NASDAQ:RNAC) Receives Consensus Rating of "Moderate Buy" from AnalystsCartesian Therapeutics, Inc. (NASDAQ:RNAC - Get Free Report) has earned an average rating of "Moderate Buy" from the ten brokerages that are covering the firm, Marketbeat.com reports. Two research analysts have rated the stock with a hold recommendation and eight have given a buy recommendation toFebruary 9, 2025 | marketbeat.comWhat is Leerink Partnrs' Forecast for RNAC FY2029 Earnings?Cartesian Therapeutics, Inc. (NASDAQ:RNAC - Free Report) - Investment analysts at Leerink Partnrs issued their FY2029 earnings estimates for shares of Cartesian Therapeutics in a note issued to investors on Wednesday, February 5th. Leerink Partnrs analyst T. Smith expects that the company will poFebruary 7, 2025 | marketbeat.com Get Cartesian Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for RNAC and its competitors with MarketBeat's FREE daily newsletter. Email Address RNAC Media Mentions By Week RNAC Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. RNAC News Sentiment▼0.500.75▲Average Medical News Sentiment RNAC News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. RNAC Articles This Week▼123▲RNAC Articles Average Week Get Cartesian Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for RNAC and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies GYRE News Today MLYS News Today WVE News Today PAHC News Today ARDX News Today COLL News Today NTLA News Today RCUS News Today AVDL News Today SYRE News Today Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:RNAC) was last updated on 5/25/2025 by MarketBeat.com Staff From Our PartnersGold Hits New Highs as Global Markets SpiralWhen Trump took office in 2017, gold was just $1,100 an ounce. By the time he left, it had soared to $1,839. ...Premier Gold Co | SponsoredWhite House to reset Social Security?Elon Musk's parting DOGE gift looks set to shock America... A single announcement by July 22nd could soon b...Altimetry | SponsoredBuffett’s favorite chart just hit 209% – here’s what that means for goldA Historic Gold Announcement Is About to Rock Wall Street For months, sharp-eyed analysts have watched the ...Golden Portfolio | SponsoredA grave, grave error.I thought what happened 25 years ago was a once- in-a-lifetime event… but how wrong I was. Because here we...Porter & Company | SponsoredIs President Trump Lying To You With This?President Trump’s economic transition isn’t without hardship. But what if there were a smart, tax-free way to ...Colonial Metals | SponsoredTrump’s Bitcoin Reserve is No Accident…Bitcoin's supply is being drained at unprecedented rates, but while most investors focus solely on Bitcoin, th...Crypto 101 Media | SponsoredTrump Exec Order 14179 is wealth “gift” to good Americans?Is President Trump’s Executive Order 14179… A secret way to restore wealth for good citizens? If you’ve ...Paradigm Press | SponsoredThis Signal Only Flashes Once Every 4 Years – And It Just TriggeredThis same signal has appeared twice before in the past 8 years — both times, it kicked off major moves in cryp...Crypto Swap Profits | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Cartesian Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Cartesian Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy RNAC Stock Free RNAC Stock Alerts